Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference Nasdaq:VOR

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference Nasdaq:VOR

CAMBRIDGE, Mass., March 01, 2021 (News) — Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021. Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.

About Vor Biopharma

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Contacts:

Investor: Constantine Davides, CFAWestwicke +1 339-970-2846 constantine.davides@westwicke.com

Media: Mary Carmichael Ten Bridge Communications +1 617-413-3543 mary@tenbridgecommunications.com

Health News Highlights

  • Headline: Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference Nasdaq:VOR
  • Check all news and articles from the Heath news updates.
Disclaimer: If you need to update/edit/remove this news or article then please contact our support team.
For Latest Updates Follow us on Google News
Bollyinside - US Local News & Breaking News Stories
Logo
Compare items
  • Total (0)
Compare
0